Optimal care of autosomal dominant polycystic kidney disease patients

Nephrology

Volumn 11, Issue 2, 2006, Pages 124-130

  Schrier, Robert W ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Hypertension; Kidney disease; Left ventricular hypertrophy

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; POLYCYSTIN 1; POLYCYSTIN 2; SARALASIN;

AUTOSOMAL DOMINANT DISORDER; BLOOD PRESSURE REGULATION; CHROMOSOME 16; CHROMOSOME 4; CLINICAL TRIAL; CYSTIC FIBROSIS; DISEASE COURSE; DOWN SYNDROME; GENE; GENETIC CORRELATION; HEALTH CARE; HEART DISEASE; HEART LEFT VENTRICLE HYPERTROPHY; HEMOPHILIA; HUMAN; HUNTINGTON CHOREA; HYPERTENSION; INTRACRANIAL ANEURYSM; KIDNEY DISEASE; KIDNEY POLYCYSTIC DISEASE; MOLECULAR BIOLOGY; MORBIDITY; MORTALITY; MYOTONIC DYSTROPHY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; REVIEW; SCREENING; SICKLE CELL ANEMIA;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DISEASE PROGRESSION; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; INTRACRANIAL ANEURYSM; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; RENIN-ANGIOTENSIN SYSTEM;

EID: 33645884413     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2006.00535.x     Document Type: Review

References (51)

1. Ecder T Fick-Brosnahan G Schrier RW. Polycystic kidney disease. In Schrier RW (ed.). Diseases of the Kidney and Urinary Tract 8th edn. Philadelphia, PA Lippincott Williams & Wilkins 2006 in press.
2. Rayer FO. The History of Albuminous Nephritis. London Wellcome Trust Centre for the History of Medicine 2005. (French text translation.)
3. Wilson P. Mechanisms of disease: Polycystic kidney disease. N. Engl. J. Med. 2004 350 151 64.
4. Hateboer N. Clinical management of polycystic kidney disease. Clin. Med. 2003 3 509 12.
5. Tao Y Kim J Schrier RW Edelstein C. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease (PKD). J. Am. Soc. Nephrol. 2005 16 46 51.
6. Tao Y Kim J Faubel S et al. Caspase inhibition reduces tubular apoptosis and proliferation and slows disease progression in polycystic kidney disease. Proc. Natl Acad. Sci. USA 2005 102 6954 9.
7. Gattone VH Wang X Harris PC Torres VE. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat. Med. 2003 9 1323 6.
8. Torres VE Wang X Qian Q Somlo S Harris PC Gattone VH. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat. Med. 2004 10 363 4.
9. Gabow PA Johnson AM Kaehny WD et al. Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Kidney Int. 1992 41 1311 19.
10. Ecder T Schrier RW. Hypertension in autosomal-dominant polycystic kidney disease: Early occurrence and unique aspects. J. Am. Soc. Nephrol. 2001 12 194 200.
11. Fick GM Johnson AM Hamamond WS Gabow PA. Causes of death in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 1995 5 2048 56.
12. Schrier RW Johnson AM McFann K Chapman AB. The role of parental hypertension in the frequency and age of onset of hypertension in offspring with autosomal dominant polycystic kidney disease. Kidney Int. 2003 64 1792 9.
13. Kelleher CL McFann KK Johnson AM Schrier RW. Characteristics of hypertension in young adults with autosomal dominant polycystic kidney disease compared with the US population. Am. J. Hypertens. 2004 17 1029 34.
14. Fick-Brosnahan G Belz M McFann K Johnson A Schrier RW. Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: A longitudinal study. Am. J. Kidney Dis. 2002 39 1127 34.
15. Fick GM Duley IT Johnson AM et al. The spectrum of autosomal dominant polycystic kidney disease in children. Kidney Int. 2005 68 2218 24.
16. Shamshirsaz AA Bekheirnia MR Kamgar M et al. Autosomal dominant polycystic kidney disease in infancy and childhood: Progression and outcome. Kidney Int. 2005 68 2218 24.
17. Chapman AB Guay-Woodford LM Grantham JJ et al. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The consortium for radiologic imaging studies of polycystic kidney disease (CRISP) cohort. Kidney Int. 2003 64 1035 45.
18. Ettinger A Kahn PC Wise HM Jr. The importance of selective renal angiography in the diagnosis of polycystic disease. J. Urol. 1969 102 156 61.
19. Valvo E Gammaro L Tessitore N et al. Hypertension of polycystic kidney disease: mechanisms and hemodynamic alternations. Am. J. Nephrol. 1985 5 176 81.
20. Anderson RJ Miller PD Linas SL et al. Role of the renin-angiotensin system in hypertension of polycystic kidney disease. Miner. Electrolyte Metab. 1979 2 137 41.
21. Bell P Hossack K Gabow P et al. Hypertension in autosomal dominant polycystic kidney disease. Kidney Int. 1988 34 683 90.
22. Chapman A Johnson A Gabow P et al. The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. N. Engl. J. Med. 1990 323 1091 6.
23. Torres VE Wilson DM Burnett JC et al. Effect of inhibition of converting enzyme on renal hemodynamics and sodium management in polycystic kidney disease. Mayo Clin. Proc. 1991 66 1010 17.
24. Watson ML Macnicol AM Allan PL et al. Effects of angiotensin converting enzyme inhibition in adult polycystic kidney disease. Kidney Int. 1992 41 206 10.
25. Harrap SB Davies DL Macnicol AM et al. Renal, cardiovascular and hormonal characteristics of young adults with autosomal dominant polycystic kidney disease. Kidney Int. 1991 40 501 8.
26. Torres VE Donovan KA Scicili G et al. Synthesis of renin by tubulocystic epithelium in autosomal-dominant polycystic kidney disease. Kidney Int. 1992 42 364 73.
27. Loghman-Adham M Soto CE Inagami T Cassis L. The intrarenal renin-angiotensin system in autosomal dominant polycystic kidney disease. Am. J. Physiol. Renal Physiol. 2004 287 F775 F788.
28. Klein IHT Lintenberg G Oey PM et al. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J. Am. Soc. Nephrol. 2001 12 2427 33.
29. Munemura C Uemasu J Kawasaki H. Epidermal growth factor and endothelin in cyst fluid from autosomal dominant polycystic kidney disease cases: possible evidence of heterogeneity in cystogenesis. Am. J. Kidney Dis. 1994 24 561 8.
30. Agarwal R Campbell R Warnock D. Oxidative stress in hypertension and chronic kidney disease: Role of angiotensin II. Semin. Nephrol. 2004 24 101 14.
31. Schrier RW Shamshirsaz A. Autosomal dominant polycystic disease: The renin-angiotensin-aldosterone system (RAAS), hypertension, and left ventricular hypertrophy. Current Medical Literature - Nephrology and Hypertension. 2004 10 49 55.
32. Chapman AB Johnson AM Rainquet S et al. Left ventricular hypertrophy in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 1997 8 1292 7.
33. Ivy DD Shaffer EM Johnson AM Kimberling WG Dobin A Gabow PA. Cardiovascular abnormalities in children with autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 1995 5 2032 6.
34. Valero FA Martinez-Vea A Bardaji A et al. Ambulatory blood pressure and left ventricular mass in normotensive patients with autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 1999 10 1020 26.
35. Ruiz-Ortega M Egido J. Angiotensin II modulates cell growth-related events and synthesis of matrix proteins in renal interstitial fibroblasts. Kidney Int. 1997 52 1497 510.
36. Ecder T Edelstein CL Chapman AB et al. Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease. Nephrol. Dial. Transplant. 1999 14 1113 16.
37. Schrier RW McFann K Johnson A et al. Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: Results of a seven-year prospective randomized study. J. Am. Soc. Nephrol. 2002 13 1733 9.
38. Ecder T Edelstein CL Fick-Brosnahan G et al. Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease. Am. J. Nephrol. 2001 21 98 103.
39. Chapman AB Johnson AM Gabow PA et al. Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 1994 5 1349 54.
40. Ecder T Chapman AB Brosnahan GM et al. Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease. Am. J. Kidney Dis. 2000 35 427 32.
41. Gall MA Borch-Johnsen K Hougaard P Nielsen FS Parving HH. Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 1995 44 1303 39.
42. Schrier RW McFann K Johnson A. Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease. Am. J. Kidney Disease 2005 46 415 23.
43. Taylor M Johnson AM Tison M Fain P Schrier RW. Earlier diagnosis of autosomal dominant polycystic kidney disease: Importance of family history and implications for cardiovascular and renal complications. Am. J Kidney Dis. 2005 46 415 23.
44. Fain P McFann K Taylor M et al. Modifier genes play a significant role in the phenotypic expression of ADPKD. Kidney Int. 2005 67 1256 67.
45. Chapman AB Rubinstein D Hughes R et al. Intracranial aneurysms in autosomal dominant polycystic kidney disease. N. Engl. J. Med. 1992 327 916 20.
46. Huston J III. Torres VE Sulivan PP Offord KP Wiebers DO. Value of magnetic resonance angiography for the detection of intracranial aneurysms in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 1993 3 1871 7.
47. Belz MM Hughes RL Kaehny WD et al. Familiar clustering of ruptured intracranial aneurysms in autosomal dominant polycystic kidney disease. Am. J. Kidney Dis. 2001 38 770 6.
48. Belz MM Fick-Brosnahan GM Hughes RL et al. Recurrence of intracranial aneurysms in autosomal-dominant polycystic kidney disease. Kidney Int. 2003 63 1824 30.
49. Rubinstein D Sandberg EJ Breeze RE et al. T2-weighted three-dimensional turbo spin-echo MR of intracranial aneurysms. AJNR Am. J. Neuroradiol. 1997 18 1939 43.
50. Schrier RW Belz MM Johnson AM et al. Repeat imaging for intracranial aneurysms in patients with autosomal dominant polycystic kidney disease with initially negative studies: A prospective ten-year follow-up. J. Am. Soc. Nephrol. 2004 15 1023 8.
51. Igarashi P Somlo S. Genetics and pathogenesis of polycystic kidney disease. Review. J. Am.Soc.Nephrol. 2002 13 2384 98.